DUBLIN – Medtronic plc, the global leader in medical technology,today announced it has received U.S. Food and Drug Administration (FDA) approval for the Abre™ venous self-expanding stent system. This ...

Medtronic has been awarded FDA approval for a device that treats venous outflow obstruction. The Dublin-based company’s Abre venous self-expanding stent system is indicated for use in the iliofemoral ...

Abre (Medtronic), a dedicated venous stent, has a 12-month primary patency rate of 88%, exceeding the performance goal for effectiveness in its pivotal investigational device exemption (IDE) trial.

This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines, when they ...